| Gene symbol | CTAG1B | Synonyms | CTAG, ESO1, CT6.1, CTAG1, LAGE-2, LAGE2B, NY-ESO-1 | Type of gene | protein-coding |
| Chromosome | X | Map location | Xq28 | dbXrefs | |
| Description | cancer/testis antigen 1B | ||||
| GTO ID | GTC1992 |
| Trial ID | NCT03697824 |
| Disease | Synovial Sarcoma |
| Altered gene | NY-ESO-1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | Letetresgene autoleucel|GSK3377794|Lete-cel |
| Co-treatment | Pembrolizumab |
| HLA | HLA-A*02:01|HLA-A*02:05|HLA-A*02:06 |
| Phase | Phase2 |
| Recruitment status | Withdrawn |
| Title | Open-Label Phase 1b/2a Clinical Trial to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered NY-ESO-1 Specific (c259) T Cells (GSK3377794) in Combination With Anti-Cancer Agents Including Pembrolizumab in HLA-A2+ Participants With NY-ESO-1 and/or LAGE-1a Positive Relapsed and Refractory Synovial Sarcoma |
| Year | 2018 |
| Country | United Kingdom |
| Company sponsor | GlaxoSmithKline |
| Other ID(s) | 209147 |
| Cohort 1 | |||||||||||
|
|||||||||||